🚀 Get ready for the excitement at the IASLC educational Amazing Case Race! 🏁✨ Don't forget to vote for your favorite case! 🗳️🙌 #WCLC24 Aakash Desai, MD, MPH Christian Rolfo Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation form.jotform.com/242185602933153

#WCLC24 IASLC academy awardees on stage at IASLC award ceremony! So proud of my friends Aakash Desai, MD, MPH Fawzi Abu Rous, MD Matt Lee, among this group of exceptionally talented young lung cancer researchers!

What an experience being part of the IASLC Academy! Highlight ✨: Got to do it with my LungCancerRx 🫁💊 team: Eric K. Singhi, MD Fawzi Abu Rous, MD Thank you to Christian Rolfo Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation and all the mentors! Congratulations to fellow participants!

Honored to be selected for this year’s IASLC Academy! Grateful to the chairs for embracing diversity not only in regional representation but also in research ideas—patient education in lung cancer is vital and represents an unmet need. #WCLC24 MD Anderson Cancer Center

🚨 Ready for the presidential symposium #WCLC2024 IASLC

1. PL02.04: HARMONI-2 Study 🧬 Exciting results from the HARMONI-2 Phase 3 study! 📊 Ivonescimab (AK112) vs. Pembrolizumab as 1L treatment for PD-L1-Positive mNSCLC shows significant improvements! 🌟 #LCSM #Oncology #WCLC24 🔍 Key takeaways: ➡️ mPFS: 11.1 vs 5.8 mos (HR:0.51) ➡️

HARMONi-2: Ivonescimab (PD-1/VEGF bispecific antibody) v Pembrolizumab as 1L Treatment for PD-L1-Positive mNSCLC First drug to show a “meaningful benefit" over pembrolizumab in a phase III trial for mNSCLC? #WCLC24 OncoAlert

LungCancerRx 🫁💊 Eric K. Singhi, MD Stephen V Liu, MD Charu Aggarwal, MD, MPH, FASCO Jarushka Naidoo Ana I. Velázquez Mañana, MD, MSc, FASCO H. Jack West, MD, FASCO Fawzi Abu Rous, MD Rafeh Naqash, MD Lei Deng, MD (He/Him) Discussant Dr. Heymach MD Anderson Cancer Center gives perspective on: ➡️ 1L landscape ➡️ Strengths and Issues (as raised in my last tweet; 1-49% and China only enrollment) Note: KN42- did not show benefit for pembro/chemo ➡️ Consistent Benefit across subgroups, manageable safety

🔥Impressive results from the HARMONI-2 trial (Ivonescimab vs Pembrolizumab in advanced PD-L1+ NSCLC) #WCLC2024 #IASLC

#WCLC24 Presidential I Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC: - 398pts - PFS HR 0.51 (11.1 v 5.82 mPFS) - benefit across histology & PDL1 🌟 Impressive data overall ❓Is this a step forward for PDL1 1-49% grp? 80% males enrolled, data needed in women IASLC

🔥🚨OncoAlert HOT OFF THE PRESS. Just presented at the presidential symposium IASLC #WCLC24 Results of #HARMONi2 trial of #Ivonescimab VS #Pembrolizumab in advanced non-small cell #LungCancer with PD-L1 >1%. ✅ Significant ⬆️mPFS 11.14 vs. 5.82 months (HR 0.51) #Benefit

Dr. Patrick Forde shared patient-level data comparing perioperative (CM77T) v neoadjuvant (CM816) nivolumab for rNSCLC. 👉🏽mEFS HR 0.61, favoring perioperative nivolumab. Without an RCT, does this answer our question for patients TODAY? Oncology Brothers Balazs Halmos Aakash Desai, MD, MPH

Normalized Membrane Ratio (NMR) of TROP2 by Quantitative Continuous Scoring is predictive of Clinical Outcomes in TROPION-Lung 01. OncoAlert #WCLC24 ✅Improved ORR and mPFS w/ DatoDxd in NMR+ vs NMR- in all comers & in pts w/ NSq-NSCLC w/o AGA. ❌No association between NMR

🚨Our Shirish Gadgeel Henry Ford Health presents an update of #MARIPOSA trial 1st line Amivantimab and Lazetinib in EGFR #NSCLC IASLC EGFR Resisters Research Summit EGFR Resisters #WCLC2024

Dr Wang: Phase 2 perioperative ivonescimab NCT05247684. 2 doses. 1o=MPR. N=60. Mostly (75%) SqCC. V impressive pCR rates 30-43% with chemo-feee approach. Higher with higher TPS and SqCC. No diff in pCR or ORR with dose. IASLC #WCLC24

Come visit the poster presenters at the Exhibit Hall, happening now! Lots of great work being shared, including by Sarah Waliany, MD, MS , super talented senior fellow from MGH Thoracic Oncology on ALK TKI resistance large dataset analysis. #WCLC24 #LCSM ALK Positive ALK+ International

Check out our work today at #WCLC24 on Proteomics-Based Target Identification for Optimizing BsAbs in #lcsm, today from 6-8PM! Poster Board # P2.11A.02 Link to review: mdpi.com/1424-8247/16/1… IASLC Aakash Desai, MD, MPH UAB O'Neal Comprehensive Cancer Center ASCO TECAG IMG Oncologists Hem-Onc Fellows Network

🔥Oncology Brothers live event at #WCLC24 to help unwrap all the new data in #NSCLC and #SCLC IASLC

Celebrating 50 years of advancements and advocacy for our patients with lung cancer with IASLC #WCLC24 Dr. Fabio Moraes Narjust Florez, MD, FASCO Sandip Patel MD

WCLC -2024 Highlights in Arabic- Stay tuned. Latest updates